Psoriatic Arthritis News

SCOTTSDALE, Ariz. — Interleukin-17 targeting, a tyrosine kinase 2 inhibitor and the “nanobody revolution” represent a promising new frontier for psoriatic arthritis, according to a speaker here.

The U.S. Department of Veterans Affairs will replace Humira with the biosimilar Hadlima on its national formulary, according to a press release from Organon, which markets biosimilar.

SCOTTSDALE, Ariz. — Understanding how guidelines and recommendations are formed can make them “most helpful” in clinical practice, according to a presentation at the Basic and Clinical Immunology for the Busy Clinician symposium.

Men with inflammatory joint diseases have more children and are less likely to be childless, compared with those without inflammatory joint diseases, according to data published in the Annals of the Rheumatic Diseases.

A lot can change in a year. But has it?

Guselkumab demonstrates consistent pharmacological effects across both patients naïve to biologics and those with an inadequate response to TNF inhibitors, according data published in Arthritis & Rheumatology.

The use of biologics to treat psoriasis does not affect antibody production after a patient has had a COVID infection or vaccination, according to a study.

Bimekizumab’s efficacy in psoriatic arthritis is “favorable” when compared with all other approved treatments in terms of both efficacy and safety, according to a systemic review and network meta-analysis published in Rheumatology.

An initiative to switch clinically stable patients from Remicade to a biosimilar significantly increased biosimilar use in rheumatology and gastroenterology clinics within the University of North Carolina health system, according to data.

Fatigue in patients with inflammatory rheumatic and musculoskeletal diseases should be addressed with tailored physical activity, psychoeducational interventions or possibly immunomodulatory treatment, according to EULAR recommendations.